Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates

Company Performance - Agios Pharmaceuticals reported a quarterly loss of $1.72 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.64, and a significant decline from earnings of $0.67 per share a year ago, indicating a negative earnings surprise of -4.88% [1] - The company generated revenues of $7.1 million for the quarter ended December 2023, missing the Zacks Consensus Estimate by 9.84%, but showing an increase from $4.31 million in the same quarter last year [1] - Over the last four quarters, Agios has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [1] Stock Performance - Agios Pharmaceuticals shares have increased by approximately 16.3% since the beginning of the year, outperforming the S&P 500, which gained 4.8% [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.58 on revenues of $9.79 million, while for the current fiscal year, the estimate is -$5 on revenues of $88.47 million [4] - The estimate revisions trend for Agios Pharmaceuticals is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [4] Industry Context - The Medical - Products industry, to which Agios belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges for stock performance [5] - Medtronic, another company in the same industry, is expected to report quarterly earnings of $1.26 per share, reflecting a year-over-year decline of -3.1%, with revenues projected at $7.95 billion, up 2.9% from the previous year [6]